Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Data shows that one dose of IdeS has favorable effect and completely removes HLA-antibodies

Regulatory information
At Hansa Medical’s Capital Markets Day in Stockholm today, one of the world’s leading transplantation experts, Professor Stanley Jordan at Cedars-Sinai Medical Center, Los Angeles, will show data from one of his ongoing studies where highly sensitized patients are desensitized and treated with Hansa Medical’s lead candidate drug IdeS prior to transplantation. 

Data will be shown from a patient with a PRA level of 100% who was treated and transplanted successfully in July this year.

The investigator-sponsored clinical phase II study, which was initiated and led by Dr. Jordan, is an open-label study to assess the safety and efficacy of IdeS in eliminating donor specific antibodies and thus prevent antibody-mediated rejection in highly sensitized patients. The study, in which IdeS is added to Dr. Jordan’s standard protocols for sensitized patients, will include up to 20 highly sensitized patients on the UNOS (United Network for Organ Sharing) waiting list. All included patients will undergo kidney transplantation and be followed up for 6 months post transplantation.

“Data that we have seen in this patient is amazing, and could potentially revolutionize the whole area of transplantation, especially in sensitized patients”, said Dr. Jordan.

“It is promising to see that IdeS is so effective in removing HLA antibodies also in this difficult group of higly sensitized patients”, commented Lena Winstedt, Clinical Research Director.

The information in this press release is disclosed pursuant to the Securities Markets Act or the Financial Instruments Trading Act. The information was released for public disclosure on November 13, 2015, at 08.45 CET.